LNTH vs NTLA
Lantheus Holdings, Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | LNTH | NTLA |
|---|---|---|
| Revenue | $1.5B | $67.7M |
| Net income | $233.6M | $-412.7M |
| Gross margin | 61.1% | 100.0% |
| Net margin | 15.2% | −609.9% |
| Return on equity | 21.4% | −53.5% |
| Diluted EPS | $3.41 | −$3.81 |
| Dividend / share | — | — |
| Payout ratio | −0.2% | — |
| Free cash flow | $259.9M | $-395.9M |
| Equity | $1.1B | $671.4M |
| Net debt / equity | 0.19× | — |
| Current ratio | 2.70× | 5.08× |
| Revenue CAGR 5y | 35.3% | 3.1% |
| Profit CAGR 5y | — | — |
LNTH bills 22.8× the revenue of NTLA, and NTLA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | LNTH | NTLA |
|---|---|---|
| FY2025 | $1.5B | $67.7M |
| FY2024 | $1.5B | $57.9M |
| FY2023 | $1.3B | $36.3M |
| FY2022 | $935.1M | $52.1M |
| FY2021 | $425.2M | $33.1M |
| FY2020 | $339.4M | $58.0M |
| FY2019 | $347.3M | $43.1M |
| FY2018 | $343.4M | $30.4M |
| FY2017 | $331.4M | $26.1M |
| FY2016 | $301.9M | $16.5M |
Net income by year
Bottom line
| Fiscal year | LNTH | NTLA |
|---|---|---|
| FY2025 | $233.6M | $-412.7M |
| FY2024 | $312.4M | $-519.0M |
| FY2023 | $326.7M | $-481.2M |
| FY2022 | $28.1M | $-474.2M |
| FY2021 | $-71.3M | $-267.9M |
| FY2020 | $-13.5M | $-134.2M |
| FY2019 | $31.7M | $-474.2M |
| FY2018 | $40.5M | $-85.3M |
| FY2017 | $123.4M | $-67.5M |
| FY2016 | $26.8M | $-31.6M |
Advertisement
AdSense · Rectangle 336×280
More in this industry